CBGA, or Cannabigerolic Acid, is a non-psychoactive cannabinoid found in the cannabis plant. It serves as a precursor to other cannabinoids and has been studied for its potential health benefits and therapeutic uses.
Chemical name:
The chemical name for CBGA is (2E)-3-(1,1-Dimethylbutyl)-4,6-dihydroxy-2-methoxy-2,2-dimethylcyclohexyl) methyl] hexa-2,5-dienoic acid.
Molecular formula:
The molecular formula for CBGA is C22H32O4.
Formula weight:
The formula weight for CBGA is 360.49 g/mol.
CAS No:
The CAS number for CBGA is 25555-57-1.
Top ten keywords from Google and Synonyms:
Synonyms include Cannabigerol carboxylic acid and CBG acid.
Health benefits of this product:
CBGA has been studied for various health benefits, including its potential as an anti-inflammatory and antispasmodic agent. It may also have potential as a treatment for certain types of cancer and neurological conditions.
Potential effects:
CBGA acts on various receptors and signaling pathways in the body, including the CB1 and CB2 cannabinoid receptors. It has been shown to exhibit anti-inflammatory and neuroprotective effects, making it a promising treatment option for conditions such as multiple sclerosis and Alzheimer's disease. Additionally, it may have potential as a cancer treatment by inhibiting the growth of certain types of cancer cells.
Product mechanism:
CBGA serves as a precursor to other cannabinoids, including THC and CBD. It is synthesized from CBG and then converted into various other cannabinoids through enzymatic processes. More research is needed to fully understand the mechanisms of action of CBGA.
Safety:
CBGA is generally considered to be safe when used appropriately. However, more research is needed to fully understand the safety profile of this compound, particularly when used in high doses or for extended periods of time.
Side effects:
There are few reported side effects associated with CBGA use. However, some people may experience mild gastrointestinal symptoms such as nausea or diarrhea.
Dosing information:
There is currently no established dosing information for CBGA due to its classification as a naturally occurring compound found in the cannabis plant. However, it should be used under medical supervision.
Conclusion:
CBGA is a non-psychoactive cannabinoid found in the cannabis plant that has been studied for its potential health benefits and therapeutic uses, including its potential as an anti-inflammatory and antispasmodic agent. While there are few reported side effects associated with CBGA use, more research is needed to fully understand its safety and efficacy. Overall, CBGA represents a promising avenue for future research into natural therapeutics for various conditions, particularly as a potential cancer treatment and neuroprotective agent. However, its legal status remains uncertain and further research is needed to fully understand its potential health benefits and risks
